[go: up one dir, main page]

DK3157531T3 - Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil - Google Patents

Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil Download PDF

Info

Publication number
DK3157531T3
DK3157531T3 DK15811714.3T DK15811714T DK3157531T3 DK 3157531 T3 DK3157531 T3 DK 3157531T3 DK 15811714 T DK15811714 T DK 15811714T DK 3157531 T3 DK3157531 T3 DK 3157531T3
Authority
DK
Denmark
Prior art keywords
stimulating
diseases
compositions
treatment
methods
Prior art date
Application number
DK15811714.3T
Other languages
English (en)
Inventor
Michael Zasloff
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Application granted granted Critical
Publication of DK3157531T3 publication Critical patent/DK3157531T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK15811714.3T 2014-06-23 2015-06-22 Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil DK3157531T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015657P 2014-06-23 2014-06-23
US14/329,627 US10040817B2 (en) 2013-10-03 2014-07-11 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PCT/US2015/036935 WO2015200195A1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Publications (1)

Publication Number Publication Date
DK3157531T3 true DK3157531T3 (da) 2021-07-05

Family

ID=54869043

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15811714.3T DK3157531T3 (da) 2014-06-23 2015-06-22 Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil

Country Status (19)

Country Link
US (10) US10040817B2 (da)
EP (1) EP3157531B1 (da)
JP (2) JP6692300B2 (da)
CN (2) CN106535902B (da)
BR (1) BR112016029917A2 (da)
CA (1) CA2951720C (da)
CY (1) CY1124554T1 (da)
DK (1) DK3157531T3 (da)
ES (1) ES2878077T3 (da)
HR (1) HRP20211005T1 (da)
HU (1) HUE054828T2 (da)
LT (1) LT3157531T (da)
MX (2) MX382442B (da)
PL (1) PL3157531T3 (da)
PT (1) PT3157531T (da)
RS (1) RS62064B1 (da)
SI (1) SI3157531T1 (da)
SM (1) SMT202100373T1 (da)
WO (1) WO2015200195A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2018222665A1 (en) * 2017-05-31 2018-12-06 Enterin Laboratories, Inc. Methods and compositions for preventing or treating inflammatory diseases
WO2019050903A1 (en) * 2017-09-08 2019-03-14 Enterin Laboratories, Inc. METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
EP3704132A4 (en) * 2017-10-30 2021-07-28 Enterin, Inc. NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM
AU2019242557A1 (en) * 2018-03-27 2020-10-15 Enterin, Inc. Methods and compositions for treating hallucinations and conditions related to the same
WO2019241503A1 (en) * 2018-06-13 2019-12-19 Enterin, Inc. Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
WO2020028810A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions and methods for treating brain-gut disorders
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
WO2020028791A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Low dosage intranasal aminosterol dosage forms and methods of using the same
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
DE69412596T2 (de) 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
WO1996008270A2 (en) 1994-09-13 1996-03-21 Magainin Pharmaceuticals Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
EP0832094B1 (en) 1995-06-07 2004-02-11 Genaera Corporation Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
PT910382E (pt) 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
CA2255856C (en) 1996-05-17 2008-05-13 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
WO1998019682A1 (en) 1996-11-01 1998-05-14 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and uses therefor
JP2002522501A (ja) 1998-08-12 2002-07-23 ジェネーラ・コーポレーション アミノステロール化合物類およびそれらの用途
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
AU2002243204A1 (en) * 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
KR20100056569A (ko) * 2002-01-28 2010-05-27 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP2527355B1 (en) 2005-04-25 2019-02-20 Enterin, Inc. Polymorphic and amorphous salt forms of squalamine dilactate
WO2009032321A2 (en) 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
CA2870671C (en) 2012-04-20 2020-05-12 Ohr Pharmaceutical Inc. Aminosteroids for the treatment of a ptp1b associated disease
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
US9504700B2 (en) 2012-12-20 2016-11-29 Mount Desert Island Biological Laboratory Methods and compositions for stimulation and enhancement of regeneration of tissues
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
CY1124554T1 (el) 2022-07-22
US20170326156A1 (en) 2017-11-16
MX2021005489A (es) 2021-06-18
WO2015200195A1 (en) 2015-12-30
US20180319837A1 (en) 2018-11-08
US20150368290A1 (en) 2015-12-24
CN106535902B (zh) 2021-05-25
US20180002370A1 (en) 2018-01-04
JP6692300B2 (ja) 2020-05-13
RS62064B1 (sr) 2021-07-30
US20170327530A1 (en) 2017-11-16
JP2017519775A (ja) 2017-07-20
MX2016017368A (es) 2017-08-24
SMT202100373T1 (it) 2021-07-12
CA2951720C (en) 2023-09-26
EP3157531A1 (en) 2017-04-26
MX382442B (es) 2025-03-13
US10208080B2 (en) 2019-02-19
HUE054828T2 (hu) 2021-10-28
HRP20211005T1 (hr) 2021-09-17
US20220220148A1 (en) 2022-07-14
BR112016029917A2 (pt) 2017-08-22
US10208079B2 (en) 2019-02-19
US10975116B2 (en) 2021-04-13
LT3157531T (lt) 2021-07-12
ES2878077T3 (es) 2021-11-18
CA2951720A1 (en) 2015-12-30
US20190194244A1 (en) 2019-06-27
US10633413B2 (en) 2020-04-28
SI3157531T1 (sl) 2021-09-30
CN113559108A (zh) 2021-10-29
US10196420B2 (en) 2019-02-05
US20190185513A1 (en) 2019-06-20
US20190194243A1 (en) 2019-06-27
CN106535902A (zh) 2017-03-22
JP7010979B2 (ja) 2022-02-10
JP2020097587A (ja) 2020-06-25
EP3157531A4 (en) 2018-05-16
PT3157531T (pt) 2021-07-01
EP3157531B1 (en) 2021-03-31
US10040817B2 (en) 2018-08-07
US20180327445A1 (en) 2018-11-15
PL3157531T3 (pl) 2021-11-15
US11440936B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
DK3157531T3 (da) Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3828194T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3220973T3 (da) Kunstigt lungesystem og fremgangsmåder til anvendelse deraf
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3812392T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3104852T3 (da) Sammensætninger og fremgangsmåde til behandling af aldring og aldersbetingede sygdomme og symptomer
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3107902T3 (da) Forbindelser og fremgangsmåder til at hæmme fascin
IL250582A0 (en) Compositions and methods for therapeutics prescreening
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3233071T3 (da) Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3364915T3 (da) Medicinsk indretning til registrering og/eller stimulering af væv
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
IL257764B (en) Methods for treatment of diseases